The Digital Bladder Diary
The Digital Bladder Diary is a medical device developed by ELAROS for the assessment, management and triage of patients with lower urinary tract symptoms. The device increases clinical accuracy, reduces clinical referrals and unnecessary hospital visits, and improves patient experience and satisfaction.
Project Lead Organisation
The use of bladder diaries is recommended in the NICE guidance for patients with lower urinary tract symptoms. Despite this, very few patients complete diaries and clinicians often struggle to incorporate them into their clinical practices. The existing standard is a paper-based system that requires clinicians to make sense of written data captured by patients. Clinicians are also expected to undertake a set of calculations in order arrive at an initial assessment, diagnose and triage decision.
A smart clinical decision tool was developed to capture data and support an efficient assessment, triage and management of these patients. The ELAROS Digital Bladder Diary is a CE mark Class 1 medical device that enables patients to monitor their own health both at home and on the move safely and discretely. Information captured by patients using an app is uploaded automatically to the ELAROS server that sits in the cloud and provides an immediate, indicative, clinical diagnosis and recommended clinical action to GPs.
The Digital Bladder Diary improves clinical accuracy and enhances the patience experience whilst delivering significant potential savings back to the NHS. Two independent health economic studies that ELAROS has commissioned indicates potential savings of: 30% in initial assessment costs, 35% reduction of inappropriate referrals from primary to secondary care, and a 10% reduction in pharmacology costs.
- ELAROS 24/7 Ltd
- Devices for Dignity HTC
- Medipex Ltd
- NHS Innovations North
- Sheffield Teaching Hospital NHS Foundation Trust
The development and evaluation of the technology have been funded by the project partners. In addition, the project has received funding awards from the Big Venture Challenge, Bionow, and the North East & North Cumbria AHSN.